The Europe Spine Biologics Market Size was valued at USD 717.98 million in 2024. The Europe Spine Biologics Market Size is expected to have 4.3% CAGR from 2025 to 2033 and be worth USD 1048.75 million by 2033 from USD 748.85 million in 2025.
Spine biologics are used during spine fusion surgery for the treatment of spinal deformities such as trauma, tumors, degenerative disc disease, and spinal cord injuries by stimulating bone growth formation through the inflammatory stage, repair stage, and remodeling stage. Biologics help in faster recovery and activate cellular growth. Therefore, the surge in the number of spinal fusion surgeries has fueled the adoption of biologics.
Spine Biologics market is growing due to advancement in technology as well as demand for better minimally surgical procedures, which make it more convenient for both the patient and doctor. Factors such as a rise in the prevalence of diseases due to the aging population and increased government funding are also driving the overall market. The major factors restraining the growth of the market are the high healthcare costs for such procedures, lack of expert professionals and unfavorable reimbursement scenarios.
The bone grafts substitute segment accounted for a major share of the market.
Key players operating in the Europe Spine Biologics Market profiled in this report are Alphatec Holdings, Inc., Depuy Synthes (Johnson & Johnson), Exactech, Inc., Globus Medical, Inc., Medtronic plc, NuVasive, Inc., Orthofix International N.V., RTI Surgical, Inc., SeaSpine, and Zimmer Biomet Holdings, Inc.
By Product Type
By Surgery Type
By Country
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region